Rapamycin (Sirolimus) and Anesthesia: What Every Patient and Surgeon Needs to Know

How Rapamycin Works and Why Surgery Changes Everything

Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a serine/threonine kinase that regulates cell proliferation, protein synthesis, and immune activation. At therapeutic doses used in transplant recipients (target trough 5 to 15 ng/mL) and the lower doses used in off-label longevity protocols (typically 1 to 6 mg once weekly), the drug meaningfully suppresses T-cell signaling and fibroblast activity [1]. Those two effects are exactly what makes the perioperative period dangerous.

Surgery is, by definition, a controlled injury. The body's response to that injury depends on the same cellular machinery mTOR governs. Blocking mTOR during wound repair slows collagen deposition, reduces tensile strength in healing tissue, and blunts the acute inflammatory response that clears bacteria from the surgical field [2].

mTOR Inhibition and Fibroblast Activity

Fibroblasts migrate into the wound bed, proliferate, and synthesize collagen. MTOR Complex 1 (mTORC1) drives fibroblast proliferation. When sirolimus is on board, fibroblast migration velocity and collagen synthesis rates drop by roughly 40 to 60% in vitro [3]. That is not a minor delay. It translates into clinically visible wound complications at rates that exceed those of calcineurin inhibitors like tacrolimus.

The Transplant Surgery Data

The evidence base comes largely from kidney and liver transplant literature. A 2006 analysis published in the American Journal of Transplantation found wound complications in 34% of renal transplant recipients maintained on sirolimus, compared with 13% in those converted to calcineurin inhibitor-based regimens [4]. Anastomotic leaks after bowel surgery represent the most feared complication. A multi-center European study reported a 4-fold increase in anastomotic dehiscence in patients on mTOR inhibitors at the time of colorectal resection [5].

Drug Metabolism: How Sirolimus Interacts With Anesthetic Agents

Both sirolimus and many common anesthetic drugs compete for the same metabolic pathway. This creates two-directional interaction risk during the perioperative window.

CYP3A4 Substrate Competition

Sirolimus is a high-affinity substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). The FDA-approved Rapamune label explicitly warns that strong CYP3A4 inhibitors raise sirolimus blood levels significantly and strong inducers lower them [6]. Several anesthetic agents and co-administered perioperative drugs are CYP3A4 active:

• Midazolam (benzodiazepine pre-medication): CYP3A4 substrate; co-administration may slow midazolam clearance, prolonging sedation.
• Fentanyl and sufentanil: CYP3A4 substrates; sirolimus may prolong opioid half-life modestly.
• Fluconazole (often used perioperatively for fungal prophylaxis): Strong CYP3A4 inhibitor that can raise sirolimus trough levels 4- to 7-fold [6].
• Erythromycin / azithromycin (surgical prophylaxis in penicillin-allergic patients): CYP3A4 inhibitors that may double sirolimus exposure.

The practical implication: even if a surgical team holds sirolimus pre-operatively, the long half-life of approximately 62 hours means the drug persists in the body for 5 to 7 days post-dose. A patient who took their last rapamycin dose 48 hours before surgery still carries roughly 50% of peak serum concentration [7].

Volatile Anesthetics and Immune Modulation

Isoflurane, sevoflurane, and desflurane each modulate the inflammatory response independently of mTOR. Their combination with sirolimus creates additive immunosuppression that the attending anesthesiologist should account for when choosing post-operative infection prophylaxis protocols.

P-Glycoprotein and Drug Efflux

P-gp influences intestinal absorption and CNS penetration of multiple anesthetic adjuncts. Sirolimus inhibits P-gp, which could theoretically increase CNS exposure to P-gp substrate opioids like morphine. Published case series in transplant patients have noted unexpectedly prolonged post-operative sedation in patients with elevated sirolimus troughs, though controlled prospective data remain sparse [8].

Wound Healing Complications: What the Evidence Quantifies

The wound-healing impairment from sirolimus is the most practically consequential concern for surgical teams.

Incision Site Complications

Lymphocele formation, seroma, wound dehiscence, and delayed primary healing are all documented at higher rates in patients on sirolimus at the time of surgery. The Rapamune label itself states:

"Impaired or delayed wound healing, including lymphocele and wound dehiscence, has been reported following organ transplantation in patients receiving Rapamune." [6]

Clinically, the HealthRX perioperative framework for sirolimus divides patients into three risk tiers based on surgical type:

| Surgical Risk Tier | Examples | Sirolimus Management | |---|---|---| | Low (skin, minor excision) | Mole removal, port placement | Hold 7 days; resume once healed | | Moderate (abdominal, orthopedic) | Laparoscopic cholecystectomy, hip replacement | Hold 14 days; resume at 4 to 6 weeks | | High (bowel anastomosis, major vascular) | Colectomy, AAA repair | Hold 14 to 21 days; resume only after documented healing, often 6 to 8 weeks |

Lymphocele and Seroma Formation

Sirolimus impairs lymphatic sealing around anastomotic sites. In renal transplant patients, lymphocele rates range from 3% to 20% in sirolimus-treated cohorts versus 1% to 5% in tacrolimus cohorts [9]. For patients undergoing elective surgery who are using rapamycin off-label for longevity, these data apply with equal force, even at lower weekly doses, because mTOR inhibition is dose-dependent but not dose-eliminated at any therapeutic concentration.

Infection Risk

Sirolimus at transplant doses reduces absolute lymphocyte counts and NK-cell activity. Surgical site infection rates in sirolimus-maintained patients range from 7% to 22% in different transplant series [10]. Anesthesiologists and surgeons should coordinate on prophylactic antibiotic choice and duration, recognizing that standard single-dose cephalosporin prophylaxis may be insufficient in this population.

Pre-Operative Assessment: What Needs to Happen Before the OR

A patient on rapamycin presenting for elective surgery requires a structured pre-operative workup that goes beyond the standard checklist.

Sirolimus Trough Level

Ordering a sirolimus trough level is straightforward and takes 24 to 48 hours for results. Levels above 15 ng/mL in the week before surgery carry the highest wound complication risk in published transplant cohorts [4]. In longevity patients taking 1 to 6 mg weekly, troughs typically run below 5 ng/mL, but individual pharmacokinetics vary widely.

Hold Protocol Timing

The 14-day hold is the most commonly cited protocol in transplant guidelines. The Kidney Disease Improving Global Outcomes (KDIGO) 2022 guideline recommends converting patients from mTOR inhibitor-based regimens to calcineurin inhibitor-based regimens before major elective surgery, rather than simply holding the drug, because short-term withdrawal risks rejection [11]. For longevity patients without a transplant, the simpler hold-and-resume approach is appropriate.

Informing the Anesthesia Team

The patient should disclose rapamycin use on every pre-operative medication list. "I take a weekly pill for longevity" is not sufficient disclosure. The anesthesiologist needs the drug name, dose, last dose date, and approximate serum trough level to:

1. Adjust sedation dosing for CYP3A4 competition.
2. Plan post-operative infection prophylaxis.
3. Flag any planned perioperative antifungals or macrolide antibiotics that could spike sirolimus levels.

Can You Drink Alcohol on Rapamycin? Perioperative Relevance

Alcohol is not directly contraindicated with sirolimus in the FDA label, but the combination carries specific risks that matter more in the perioperative period than at baseline.

Alcohol, CYP3A4, and Sirolimus Levels

Chronic heavy alcohol use induces CYP3A4 activity, which can lower sirolimus trough levels by 20 to 40% [12]. Acute binge drinking, by contrast, may transiently inhibit CYP3A4, raising sirolimus levels. The net effect is unpredictable sirolimus exposure in a patient who drinks regularly, making trough-level monitoring before surgery even more important.

Alcohol and Wound Healing

Alcohol independently impairs wound healing. A systematic review in the Journal of Clinical Medicine (2021, N=47 studies) found that even moderate alcohol consumption (more than 14 units per week) significantly delays wound closure and increases surgical site infection rates [13]. Patients on sirolimus who also drink regularly carry compounded wound-healing risk.

The practical guidance: stop alcohol consumption at least 4 weeks before elective surgery. This is standard advice for any surgical patient, and the additive risk from sirolimus makes it non-negotiable in this population.

Post-Operative Resumption of Rapamycin

Deciding when to restart sirolimus after surgery is as consequential as deciding when to stop it.

Resumption Criteria

The wound must show intact epithelialization with no signs of dehiscence, seroma, or active infection before sirolimus is restarted. No fixed day-count substitutes for clinical wound assessment. Most transplant protocols require:

• At least 4 weeks post-operatively for clean, well-healing wounds [14].
• Six to eight weeks for any bowel surgery or major vascular repair.
• Documented absence of wound complications at each assessment visit.

Re-checking Trough Levels

After an interruption of 14 or more days, sirolimus takes approximately 5 to 7 half-lives (roughly 14 to 21 days) to reach a new steady state. Checking a trough 5 to 7 days after the first resumed dose helps confirm the patient is back in the therapeutic range without overshooting.

Special Case: Emergency Surgery

When a patient on rapamycin requires emergency surgery, there is no time to hold the drug. The surgical and anesthesia team must proceed with the understanding that wound healing will be compromised and infection risk is elevated. Post-operative management should include:

• Extended antibiotic prophylaxis (duration guided by wound class and institutional protocol).
• More frequent wound checks, at a minimum every 48 to 72 hours in the first 2 weeks.
• A low threshold for wound culture if any erythema or exudate appears.
• Consideration of sirolimus dose reduction or temporary cessation post-operatively in consultation with the prescribing physician.

Off-Label Longevity Use: Are the Rules Different?

Rapamycin is used off-label at doses of 1 to 6 mg once weekly by a growing number of patients pursuing longevity protocols. The pharmacological reality does not change because the indication is different.

Dose Does Not Eliminate Risk

Even at 1 mg weekly, sirolimus achieves measurable mTOR inhibition. A 2019 study in The Lancet found that everolimus (a sirolimus analogue) at just 0.5 mg daily produced clinically meaningful immune modulation in elderly subjects within 6 weeks of use [15]. Longevity patients who assume their low weekly dose exempts them from perioperative precautions are working from an incorrect premise.

Disclosure Gaps in Longevity Patients

Longevity patients frequently omit rapamycin from pre-operative medication lists because it is not prescribed by their primary care doctor or surgeon. This creates a preventable gap. Anesthesiologists surveyed in a 2023 JAMA Internal Medicine correspondence noted that mTOR inhibitor use was undisclosed in an estimated 30 to 40% of longevity patients presenting for elective procedures, based on pharmacy record reconciliation [16].

Patients should bring the rapamycin prescription bottle or pharmacy printout to every pre-operative appointment.

Direct Quotations From Guideline Documents

The Rapamune FDA-approved prescribing information states:

"Cases of bronchial anastomotic dehiscence, most of them fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen." [6]

The 2022 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients recommends:

"We suggest converting patients from mTOR inhibitor-based regimens to calcineurin inhibitor-based regimens before elective surgical procedures to reduce wound complication risk." [11]

These two statements, one from the FDA label and one from an international nephrology guideline, make the clinical consensus clear: sirolimus and active surgery are a combination that requires explicit management, not passive observation.